# TRIM52

## Overview
TRIM52 is a gene that encodes the protein tripartite motif containing 52, which is a member of the tripartite motif (TRIM) family of proteins. This family is characterized by the presence of a RING domain, which in TRIM52 is notably the largest among human TRIM proteins, and is crucial for its function as an E3 ubiquitin ligase. The protein plays a significant role in various cellular processes, including protein ubiquitination and degradation, which are essential for maintaining cellular homeostasis. TRIM52 is involved in antiviral defense mechanisms, particularly against the Japanese encephalitis virus, and has been implicated in the regulation of cell proliferation and stress responses. Its rapid degradation, due to a unique repetitive acidic loop in its RING domain, makes it a model for studying protein turnover. Additionally, TRIM52 has been associated with several cancers, where it influences oncogenic pathways, highlighting its potential as a therapeutic target (Fan2016TRIM52; Zhang2018TRIM52; Hacker2019A).

## Structure
TRIM52 is a non-canonical member of the TRIM protein family, characterized by its unique domain composition. It contains a RING domain and a B-box domain but lacks the coiled-coil region typically found in other TRIM proteins (Short2006Subclassification; Sardiello2008Genomic). The RING domain of TRIM52 is the largest encoded in the human genome and includes a significantly expanded loop 2 region, which is 139 amino acids long and rich in acidic D/E residues. This loop is predicted to be unstructured at physiological pH (Hacker2019A). The RING domain is crucial for TRIM52's E3 ubiquitin ligase activity, which is essential for its function in protein ubiquitination and degradation (Fan2016TRIM52).

TRIM52's rapid degradation is attributed to all three of its domains, with the repetitive acidic loop in the RING domain being a significant destabilizing factor (Hacker2019A). Despite its instability, TRIM52 plays a role in antiviral activity, particularly against the Japanese encephalitis virus, by mediating the ubiquitination and degradation of viral proteins (Fan2016TRIM52). The protein's structure and function are influenced by its unique domain composition and rapid proteasomal turnover.

## Function
TRIM52 is a member of the tripartite motif (TRIM) family, characterized by its RING domain, which is the largest among human TRIM proteins. It plays a crucial role in cellular processes, including ubiquitination, where it functions as an E3 ubiquitin ligase. This activity is essential for tagging proteins for degradation via the proteasome pathway, a process critical for maintaining protein homeostasis within cells (Fan2016TRIM52; Hacker2019A).

In healthy human cells, TRIM52 is involved in regulating the cell cycle and cellular proliferation. It influences the activity of p53, a key tumor suppressor protein, by ubiquitinating its inhibitor, PPM1A. This action suppresses p53-dependent cell-cycle arrest, thereby promoting cell proliferation (Venuto2019E3; Hacker2019A). TRIM52 is also implicated in cellular stress responses, particularly related to Golgi stress, where its expression is upregulated under specific stress conditions (Hacker2019A).

TRIM52 is rapidly degraded in cells, with a half-life of approximately 3.5 minutes, due to a destabilizing repetitive acidic loop in its RING domain. This rapid turnover is independent of its E3 ligase activity, making TRIM52 a model for studying protein degradation mechanisms (Hacker2019A).

## Clinical Significance
TRIM52 has been implicated in several cancers due to its altered expression levels and interactions. In hepatocellular carcinoma (HCC), TRIM52 is up-regulated, promoting cell proliferation, migration, and invasion through the ubiquitination of PPM1A, a tumor suppressor that inhibits the Smad2/3 signaling pathway. This suggests TRIM52 as a potential therapeutic target in HCC (Zhang2018TRIM52).

In lung cancer, TRIM52 is also overexpressed, enhancing cell proliferation and invasiveness via the Wnt/β-catenin signaling pathway. Downregulation of TRIM52 leads to cell cycle arrest and reduced cancer cell aggressiveness, indicating its role in lung cancer progression (Mu2019TRIM52).

TRIM52 is similarly up-regulated in ovarian cancer, where it promotes oncogenic processes through the NF-kB signaling pathway. Knockdown of TRIM52 results in decreased tumor growth and increased apoptosis, highlighting its potential as a therapeutic target (Yang2018TRIM52).

Additionally, a novel fusion gene, TRIM52-RACK1, has been identified in oral squamous cell carcinoma, promoting tumor progression and suggesting its potential as a therapeutic target (Pan2020Identification). These findings underscore the clinical significance of TRIM52 in cancer development and progression.

## Interactions
TRIM52 is known to interact with several proteins, playing significant roles in various cellular processes. In hepatocellular carcinoma (HCC), TRIM52 interacts with protein phosphatase, Mg2+/Mn2+ dependent 1A (PPM1A), leading to its ubiquitination and degradation. This interaction promotes the proliferation, migration, and invasion of HCC cells by decreasing PPM1A levels, which are associated with tumor suppression (Zhang2018TRIM52).

In the context of viral infections, TRIM52 interacts with the Japanese encephalitis virus (JEV) nonstructural protein 2A (NS2A). This interaction results in the ubiquitination and proteasome-dependent degradation of NS2A, thereby inhibiting JEV replication. The RING domain of TRIM52 is crucial for this E3 ubiquitin ligase activity, which facilitates the degradation of NS2A (Fan2016TRIM52).

In colorectal cancer, TRIM52 interacts with SHP2, promoting its polyubiquitination and affecting the STAT3 signaling pathway. This interaction influences cell proliferation and apoptosis, highlighting TRIM52's role in modulating oncogenic pathways (Pan2019TRIM52). 

These interactions underscore TRIM52's involvement in both oncogenic processes and antiviral defense mechanisms.


## References


[1. (Mu2019TRIM52) Xiaoyan Mu, Hegen Li, Lei Zhou, and Weijie Xu. Trim52 regulates the proliferation and invasiveness of lung cancer cells via the wnt/β‑catenin pathway. Oncology Reports, April 2019. URL: http://dx.doi.org/10.3892/or.2019.7110, doi:10.3892/or.2019.7110. This article has 5 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/or.2019.7110)

[2. (Venuto2019E3) Santina Venuto and Giuseppe Merla. E3 ubiquitin ligase trim proteins, cell cycle and mitosis. Cells, 8(5):510, May 2019. URL: http://dx.doi.org/10.3390/cells8050510, doi:10.3390/cells8050510. This article has 98 citations and is from a peer-reviewed journal.](https://doi.org/10.3390/cells8050510)

[3. (Pan2019TRIM52) Shengli Pan, Yingying Deng, Jun Fu, Yuhao Zhang, Zhijin Zhang, Xiaokun Ru, and Xianju Qin. Trim52 promotes colorectal cancer cell proliferation through the stat3 signaling. Cancer Cell International, March 2019. URL: http://dx.doi.org/10.1186/s12935-019-0775-4, doi:10.1186/s12935-019-0775-4. This article has 36 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12935-019-0775-4)

[4. (Short2006Subclassification) Kieran M. Short and Timothy C. Cox. Subclassification of the rbcc/trim superfamily reveals a novel motif necessary for microtubule binding. Journal of Biological Chemistry, 281(13):8970–8980, March 2006. URL: http://dx.doi.org/10.1074/jbc.m512755200, doi:10.1074/jbc.m512755200. This article has 264 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1074/jbc.m512755200)

[5. (Hacker2019A) Kathrin Hacker, Stefan Benke, Benedikt Agerer, Sara Scinicariello, Valentina Budroni, and Gijs A. Versteeg. A repetitive acidic region contributes to the extremely rapid degradation of the cell-context essential protein trim52. Scientific Reports, May 2019. URL: http://dx.doi.org/10.1038/s41598-019-44359-0, doi:10.1038/s41598-019-44359-0. This article has 2 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/s41598-019-44359-0)

[6. (Pan2020Identification) Tao Pan, Yong-guo Li, Ke-yi Li, Cheng Chen, Kai Xu, Dao-ying Yuan, Bo Zou, and Zhen Meng. Identification of a novel fusion gene, trim52-rack1, in oral squamous cell carcinoma. Molecular and Cellular Probes, 52:101568, August 2020. URL: http://dx.doi.org/10.1016/j.mcp.2020.101568, doi:10.1016/j.mcp.2020.101568. This article has 0 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.mcp.2020.101568)

[7. (Yang2018TRIM52) Weihong Yang, Li Liu, Caixia Li, Ning Luo, Rong Chen, Li Li, Fudong Yu, and Zhongping Cheng. Trim52 plays an oncogenic role in ovarian cancer associated with nf-kb pathway. Cell Death &amp; Disease, September 2018. URL: http://dx.doi.org/10.1038/s41419-018-0881-6, doi:10.1038/s41419-018-0881-6. This article has 60 citations.](https://doi.org/10.1038/s41419-018-0881-6)

[8. (Fan2016TRIM52) Wenchun Fan, Mengge Wu, Suhong Qian, Yun Zhou, Huanchun Chen, Xiangmin Li, and Ping Qian. Trim52 inhibits japanese encephalitis virus replication by degrading the viral ns2a. Scientific Reports, September 2016. URL: http://dx.doi.org/10.1038/srep33698, doi:10.1038/srep33698. This article has 53 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep33698)

[9. (Zhang2018TRIM52) Yi Zhang, Ran Tao, Shan-Shan Wu, Cui-Cui Xu, Jie-Ling Wang, Jie Chen, Yong-Sheng Yu, Zheng-Hao Tang, Xiao-Hua Chen, and Guo-Qing Zang. Trim52 up-regulation in hepatocellular carcinoma cells promotes proliferation, migration and invasion through the ubiquitination of ppm1a. Journal of Experimental &amp; Clinical Cancer Research, June 2018. URL: http://dx.doi.org/10.1186/s13046-018-0780-9, doi:10.1186/s13046-018-0780-9. This article has 41 citations.](https://doi.org/10.1186/s13046-018-0780-9)

[10. (Sardiello2008Genomic) Marco Sardiello, Stefano Cairo, Bianca Fontanella, Andrea Ballabio, and Germana Meroni. Genomic analysis of the trim family reveals two groups of genes with distinct evolutionary properties. BMC Evolutionary Biology, August 2008. URL: http://dx.doi.org/10.1186/1471-2148-8-225, doi:10.1186/1471-2148-8-225. This article has 220 citations.](https://doi.org/10.1186/1471-2148-8-225)